BUZZ-Oncolytics Biotech Inc: Completes enrollment in colon cancer study

Wed Feb 18, 2015 8:03am EST
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Canadian biotech company's U.S. shares up about 15 pct at 83 cents premarket

** Oncolytics says it completes enrollment for mid-stage study testing its lead drug, reolysin, in patients with colorectal cancer

** FDA has granted reolysin orphan drug status to fight pancreatic, ovarian cancer

** The designation is granted to drugs developed to treat rare diseases, offering the developer several incentives, including seven-year marketing exclusivity in the U.S.

** Reolysin is being tested for use in a plethora of cancers, both alone and in combination with chemotherapy

** Up to Tuesday's close, stock had risen 1.4 pct since Nov. 6, when the company posted a smaller-than-expected Q3 loss